Petros Pharmaceuticals(US:PTPI)2023-08-14 21:03Financial Performance - As of June 30, 2023, Petros had cash of approximately $7.4 million and an accumulated deficit of approximately $94.7 million[109]. - The company experienced net losses and negative cash flows from operations since inception, using approximately $1.3 million in cash for operations during the six months ended June 30, 2023[109]. - Petros raised gross proceeds of $15 million in July 2023 to fund its operations and OTC progress through 2024[111]. - The company recorded a net loss of $3,931,830 for the six months ended June 30, 2023, compared to a net loss of $1,986,016 in 2022[144]. - The company experienced a net loss of $3.9 million for the six months ended June 30, 2023, compared to a net loss of $1.99 million for the same period in 2022, reflecting a worsening financial performance[207][208]. - Net sales for the six months ended June 30, 2023, were $4,511,983, a decrease of 32% compared to $6,651,685 for the same period in 2022[144]. - Net sales for the three months ended June 30, 2023, were $1,994,011, a decrease of $2,192,505 or 52% compared to the same period in 2022[172][180]. - The company’s gross billings for the six months ended June 30, 2023, were $7,756,466, down from $16,785,478 in the same period of 2022[234]. - Adjusted EBITDA for the three months ended June 30, 2023, was $(1,592,697), a decrease from $201,717 in the same period of 2022[230]. Sales and Revenue - Prescription Medicines sales decreased by $2,366,255, while Medical Devices sales increased by $226,553 during the same period[152]. - Gross profit for the six months ended June 30, 2023, was $3,447,384, or 76% of net sales, down from $5,530,125, or 83% of net sales in 2022[155]. - Gross profit for the three months ended June 30, 2023, was $1,480,154, or 74% of net sales, down from $3,537,296 or 84% of net sales in the same period of 2022[184]. - The company experienced product returns of $416,254 for the three months ended June 30, 2023, compared to $3,620,326 in the same period of 2022[233]. - The reserves for product returns as of June 30, 2023, were $2.6 million, compared to $2.3 million and $3.8 million for the same dates in 2022 and 2021, respectively[133]. Expenses and Liabilities - Selling, general and administrative expenses decreased by $2,734,111 or 38% during the six months ended June 30, 2023, compared to the same period in 2022[160]. - Selling, general and administrative expenses decreased by $967,012 or 30% during the three months ended June 30, 2023, compared to the same period in 2022[188]. - Research and development expenses increased to $1,185,668 for the six months ended June 30, 2023, from $826,602 in 2022[144]. - Research and development expenses for the three months ended June 30, 2023, were $866,575, an increase of $445,333 or 106% compared to the same period in 2022[192]. - Total liabilities decreased by $3,389,941 due to the settlement with Vivus during the six months ended June 30, 2022, with no similar activity in 2023[161]. - Interest expense related to a promissory note was $136,799 for the three months ended June 30, 2023, down from $150,372 in the same period of 2022[197]. Financing and Capital - The company is evaluating various financing strategies, including secured or unsecured debt, convertible debt, and equity offerings to meet its liquidity needs for the next twelve months[111]. - The company plans to finance operations through cash on hand and is exploring various financing strategies, including secured or unsecured debt and equity offerings[201]. - The company raised approximately $15 million in a private placement on July 17, 2023, intended for general corporate purposes and to support operations[215]. - The Series A Preferred Shares issued in the private placement will have an 8% annual dividend, compounded monthly, with potential increases to 15% under certain conditions[220]. - The company is evaluating potential asset acquisitions and business combinations to expand its service offerings, which may require additional capital[205]. Product and Market Strategy - Petros has terminated its exclusive license to H100™ from Hybrid as of May 11, 2023, refocusing on its ED product portfolio[108]. - The company holds the exclusive rights to sell Stendra® in the U.S., Canada, South America, and India, having paid a one-time fee of $70 million for the license[107]. - Petros is conducting non-clinical consumer studies for the potential FDA approval of Stendra® for OTC use, which could significantly increase product sales[107]. - The company maintains a return policy allowing customers to return Stendra® within six months prior to expiration and up to one year after expiration[133]. - As of June 30, 2023, four customers accounted for approximately 92% of Stendra® net sales, with individual contributions of 33%, 24%, 22%, and 14%[150].